Mainstream

ANI Pharmaceuticals beats top-line and bottom-line estimates; raises FY25 outlook

ANI Pharmaceuticals beats top-line and bottom-line estimates; raises FY25 outlook

Post ContentanipRead More

You might also be interested in reading Solana Chain GDP Hits $342M as RWA Market Cap Tops $2B.

August 8, 2025
In Mainstream